Questionnaire

1. Numerous studies have shown that the overexpression of VEGFs and their interactions with VEGFRs:

2. In patients with gastric cancer, positive immunohistochemical staining for VEGF-A has been correlated with:

3. VEGF-A is the central regulator of tumour angiogenesis, endothelial proliferation, permeability, and survival, and plays a key role mainly in the initiation of the formation of new blood vessels.

4. Ramucirumab, a fully human IgG monoclonal antibody, binds with high affinity to the extracellular VEGF-binding domain of:

5. In binding with high affinity to a specific epitope on the extracellular domain of VEGFR-2, ramucirumab blocks binding of:

6. From the REGARD study of ramucirumab monotherapy versus placebo for the treatment of advanced gastric/GOJ adenocarcinoma, ramucirumab was found to:

7. Adverse events were the most common reason for study drug discontinuation in the REGARD trial.

8. Compared with placebo in the REGARD study, ramucirumab was associated with increased rates of:

9. The RAINBOW trial of ramucirumab or placebo plus paclitaxel demonstrated that ramucirumab plus paclitaxel:

10. For second- or later-line treatment of advanced gastric/GOJ adenocarcinomas in patients with contraindications for chemotherapy, ESMO recommends the use of: